Citations

Clear

4207 citation(s) found for "Chen, Yu".

Emerging Therapies in Autosomal Dominant Polycystic Kidney Disease
Chen, Christopher Y. , Hadla, Mohamad , Khambati, Ibrahim, Kashyap, Sonu , Westerfield, Vanessa , Fedeles, Sorin , Besse, Whitney , Hopp, Katharina , Harris, Peter C. , Patel, Vishal , Chini, Eduardo N. , Salih, Mahdi , Chini, Eduardo, Barry, Michael A , Chebib, Fouad T , Harris, Peter C , Hadla, Mohamad , Fedeles, Sorin V. , Patel, Vishal , Khambati, Ibrahim, Westerfield, Vanessa , Barry, Michael A. , Chebib, Fouad T.

Mayo Clinic

Kidney360 | December 12, 2025 | Volume: 7 | Issue: 7 | Pages: 1662-1676

10.34067/kid.0000001109 | PMID 41385299 Get It

Autosomal dominant polycystic kidney disease is the most common inherited kidney disorder and a leading monogenic cause of kidney failure. Reduction or loss of polycystin-1 and polycystin-2 function disrupts ciliary calcium signaling, elevates cyclic AMP (cAMP), reprograms cellular metabolism, and activates proliferative cascades that drive cyst expansion. Tolvaptan, a vasopressin V2 receptor antagonist, established cAMP modulation as a disease-modifying strategy but is limited by aquaretic effects and hepatotoxicity risk. This review highlights emerging therapeutic strategies in clinical trial development that extend beyond vasopressin antagonism. Gene-directed therapies aim to restore polycystin dosage, including anti–miR-17 oligonucleotides ( e.g ., farabursen) and pharmacochaperones that rescue misfolded polycystin-1 and restore trafficking in select PKD1 missense variants ( e.g ., VX-407). Paracrine signaling can be modulated with anti–pregnancy-associated plasma protein A antibodies that reduce insulin-like growth factor-1 bioavailability in cystic microenvironments. Metabolic reprogramming is targeted by agents such as metformin, bempedoic acid, glucagon-like peptide-1 receptor agonists, and structured dietary interventions. Sodium-glucose cotransporter 2 inhibitors hold theoretical promise but await definitive results from ongoing trials. A novel cAMP-lowering strategy through phosphodiesterase-4 activation is advancing toward clinical testing. Looking ahead, gene therapy, and genome editing offer the potential to raise polycystin levels above the threshold for cystogenesis, although challenges in vector capacity, kidney-specific delivery, and durability remain. Artificial intelligence–guided discovery, coupled with human organoid platforms, is accelerating therapeutic repurposing and rational combination design. Collectively, these advances signal a transition toward a layered, mechanism-guided framework in which vasopressin blockade is integrated with metabolic, other signaling, and genotype-specific therapies. As biomarkers and risk stratification tools mature, autosomal dominant polycystic kidney disease management is poised to become increasingly precise, tolerable, and effective.
A Web‐Based Calculator for Hematopoietic Progenitor Cell Collections: App Development and Retrospective Assessment
Roth, Maxwell T. , Liu, Jun , Shah, Sanjana , Shao, Claire , Chen, Maria Y. , Haj, Amelia K. , Feeney, Dennis M., Munkacsy, Kendra, Christiansen, Nelya, Geary, Kristine, Sarhan, Suhayla, Callanan, Colleen, Ferrara, Stephanie, Covington, Mischa L. , Manis, John , Spitzer, Thomas R. , Brunker, Patricia A. R. , Grewal, Eric P , Covington, Mischa L , Chai, Li , Brunker, Patricia A R , Ruby, Kristen N , Grewal, Eric P. , Feeney, Dennis, Christiansen, Nelya, Ferrara, Stephanie, Stowell, Sean R. , Ruby, Kristen N.

Mayo Clinic

Journal of Clinical Apheresis | December 11, 2025 | Volume: 40 | Issue: 6 | Pages: No page available

10.1002/jca.70080 | PMID 41378729 Get It

ABSTRACT A major challenge in hematopoietic progenitor cell apheresis is determining the whole blood (WB) volume to process to achieve a CD34+ cell collection goal. We developed a web‐based calculator app that uses the Collection Efficiency 2 (CE2) model to estimate personalized WB processing volumes needed to reach a prescribed CD34+ cell collection goal. Retrospective evaluation of the app using collection data from two academic medical centers showed that actual processed WB volumes were frequently higher than the app's recommendations. The frequency of potential under‐collection events is predicted to be low had the app‐calculated volumes been utilized. Our findings suggest that using the app's recommendations may lower total WB processing volumes, reducing over‐collection and time spent on the apheresis machine, while maintaining a low under‐collection risk profile.
Multisystem Caliber-Persistent Arteriopathy Syndrome: A Novel Congenital Vasculopathy Associated with a Risk of Multiorgan Hemorrhage
Xu, Guangtao , Jin, Xin , Shi, Chaoqun, Zeng, Xiansi , Li, Wanlu , Chen, Shipiao, Xu, Long , Zhu, Jia, Li, Feng , Hu, Bo, Yuan, Jun , Chen, Deqing , Zhu, Jia

Mayo Clinic

No container title available | December 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8074903/v1 Get It

Abstract This study delineates a novel multisystem caliber-persistent arteriopathy syndrome, fundamentally redefining the classical Dieulafoy's lesion from a localized gastrointestinal anomaly to a systemic congenital vasculopathy. Through integrated histopathological and genomic analysis of a forensic autopsy case, we identified pervasive arterial remodeling across seven organ systems— characterized by absent physiological tapering— indicating developmental angiogenic dysregulation. Whole-genome sequencing uncovered pathogenic variants in PDE8B , LRCH1 , and ADA genes, with functional enrichment analyses implicating dysregulated purine–cAMP signaling and cytoskeletal organization as core pathogenic mechanisms. These findings establish a genetic basis for the observed pan-vascular phenotype and highlight the necessity of systematic vascular screening in cases of unexplained multiorgan hemorrhage. This work provides a foundational framework for diagnosing and investigating congenital vascular malformations with hemorrhagic risk, urging a paradigm shift in clinical evaluation and etiological assessment.
Green-friendly and biocompatible deep eutectic solvents for pharmaceuticals, biocatalysis, and biosensing applications
Wang, Yu , Zheng, Xueliang, Li, Jing , Chen, Zhihao , Wang, Tongtong , Miao, Wenjie, Wang, S. J., Li, Si , Jiang, Tingting , Miao, Wenjie, Wang, Shuocong, Jiang, Tingting

Mayo Clinic

Green Chemistry | December 10, 2025 | Volume: 28 | Issue: 3 | Pages: 1316-1345

10.1039/d5gc06075c Get It

Traditional solvents face limitations in environmental friendliness, biocompatibility, and functional tunability, which restrict their use in pharmaceuticals, biocatalysis, and biosensing.
Ultrasound Localization Microscopy to Assess the Intrarenal Microvasculature in Autosomal Dominant Polycystic Kidney Disease
Huang, Chengwu , Abd-Elfattah, Ahmed Saleh , DeRuiter, Ryan M. , Zhang, Nathan , Knoll, Kate M , Petersen, Kendra E. , Wu, Tao , Hogan, Marie C. , Eirin, Alfonso , Lerman, Lilach O. , Irazabal, María V. , Abdelfattah, Ahmed , Zhang, Youwen, Hogan, Marie C , Eirin, Alfonso , Lerman, Lilach O , Irazabal, Maria V , Huang, Chengwu , DeRuiter, Ryan , Petersen, Kendra E , Zhang, Nathan , Zhang, Youwen , Chen, Shigao

Mayo Clinic

Journal of the American Society of Nephrology | December 9, 2025 | Volume: 37 | Issue: 6 | Pages: 1221-1236

10.1681/asn.0000000968 | PMID 41563237 Get It

Key Points The kidney microvasculature was quantified reliably in human autosomal dominant polycystic kidney disease early on, using super-resolution ultrasound localization microscopy. Microvascular parameters correlated with structural and functional indices, constituting promising biomarkers to evaluate noncystic parenchyma. Microvascular parameters may serve to assess disease severity and monitor progression from the early stages of the disease. Background In vitro studies in individuals with autosomal dominant polycystic kidney disease (ADPKD) have shown extensive intrarenal microvascular remodeling. However, analyses have been limited to the time of kidney failure because of the invasive nature of current methodologies to assess the intrarenal microvasculature. We hypothesized that super-resolution ultrasound microvascular imaging, known as ultrasound localization microscopy, enabled by high-framerate ultrasound imaging and microbubble localization and tracking postprocessing techniques, would safely, reliably, and reproducibly assess the intrarenal microvasculature in individuals with ADPKD at an early stage of the disease. Methods We prospectively enrolled young (<40 years of age), well-characterized, early-stage (eGFR >90 ml/min per 1.73 m 2 ) individuals with ADPKD, and sex–age 1:1 matched controls ( n =17 each) and assessed the intrarenal microvasculature using ultrasound localization microscopy. We determined the intersonographer reliability, intraobserver repeatability, and interobserver reproducibility of microvascular parameters in both groups, and the day-to-day variability in the control group. Microvascular parameters were correlated with structural (total kidney volume) and functional (eGFR) markers in individuals with ADPKD. Results Ultrasound localization microscopy provided a super-resolved map of the intrarenal microvasculature in ADPKD and matched controls. Intrarenal microvascular parameters ( e.g ., vessel density) were quantified in a safe, reliable (intraclass correlation coefficients, 0.96; 95% confidence interval, 0.91 to 0.98), reproducible (intraclass correlation coefficient, 0.96; 95% confidence interval, 0.93 to 0.98), and repeatable (coefficient of variations, 3.6%) manner. In control individuals, the day-to-day variability of most parameters was low, with coefficient of variation ranging from 1.8% to 10.7%. Microvascular parameters differed in individuals with ADPKD compared with controls, despite preserved eGFR. Interestingly, cortical vessel density and its derived perfusion correlated directly with eGFR, whereas tortuosity indices presented an inverse correlation. Conclusions Ultrasound localization microscopy provided a safe and reliable in vivo assessment of the human intrarenal microvasculature.
(140) Percent Change in Total Motile Sperm After IUI Preparation Predicts IVF Fertilization and Blastulation Outcomes
Schrup, S, Chen, ⁠Vittor Pelanda, Guillén-Lozoya, A.H. , Chen, V, Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | December 9, 2025 | Volume: 22 | Issue: Supplement_4 | Pages: No page available

10.1093/jsxmed/qdaf320.140 Get It

Abstract Introduction Many couples who do not achieve pregnancy with intrauterine insemination (IUI) subsequently pursue in vitro fertilization (IVF). While the impact of semen parameters on IUI outcomes is well established, it remains unclear whether characteristics of sperm following IUI preparation predict future IVF success. Many couples who do not achieve pregnancy with intrauterine insemination (IUI) subsequently pursue in vitro fertilization (IVF). While the impact of semen parameters on IUI outcomes is well established, it remains unclear whether sperm characteristics following IUI preparation predict future IVF success. Here we study a novel, clinically accessible marker of sperm quality – percent change in total motile sperm (TMS) after IUI sperm wash-that may predict fertilization and blastulation outcomes in subsequent IVF cycles. Objective This aims to evaluate the association between changes in total motile sperm (TMS) after IUI sperm wash and fertilization rates in subsequent IVF cycles.This study aims to evaluate the association between changes in TMS after IUI sperm wash and fertilization and blastulation rates in subsequent IVF cycles. Methods In this retrospective study, we identified couples at a single academic center who failed to achieve a live birth following IUI and subsequently underwent IVF with the same partner. To minimize confounding, only couples with a diagnosis of unexplained infertility or male factor infertility were included. In patients who underwent multiple IUIs (median of 2), the cycle with the greatest percent decrease in TMS was selected for analysis. Additional predictive variables of female partner age, male partner age, pre-wash TMS, and insemination method were assessed. A stepwise variable selection method was utilized to identify predictors of fertilization rate and complete blastulation failure, with linear and logistic regression models of selected variables developed, respectively. Results From the cohort of 388 couples, the median fertilization rate during IVF was 56% (IQR 43%–70%). Thirteen percent of couples experienced complete blastulation failure. Change in TMS was selected as a predictor of both fertilization rate and blastulation failure. A 10% greater decline in TMS after IUI sperm wash was associated with a 1.02% lower fertilization rate (p=0.052), after adjustment for insemination method. A 10% greater decrease in TMS was associated with a 1.22-times (95% CI 1.04, 1.48) increased odds of blastulation failure (p=0.023) after adjusting for female partner age. Conclusions A greater percent decrease in TMS following IUI sperm wash is associated with lower fertilization rates and a higher odds of blastulation failure in subsequent IVF cycles. These findings support the hypothesis that significant declines in TMS after sperm preparation may reflect underlying sperm quality defects not detected by routine semen analysis, yet still relevant to fertility outcomes. By identifying sperm quality issues not apparent on standard semen analysis, these findings offer a new tool for risk stratification and counseling of couples transitioning from IUI to IVF. Disclosure No
Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case series
Nassief, George , Morecroft, Renée , Phillipps, Jordan , Chen, David , Ansstas, George , Chen, David Y. , Morecroft, Renee A

Mayo Clinic

Melanoma Management | December 9, 2025 | Volume: 12 | Issue: 1 | Pages: No page available

10.1080/20450885.2025.2598476 | PMID 41363192 Get It

Immunotherapy and Radiation for Clinical Perineural Invasion in Cutaneous Squamous Cell Carcinoma
Morecroft, Renée , Phillipps, Jordan , Gou, Lang, Bhatt, Alok A. , Kim, Sungjune , Mohammadi, Homan , Dronca, Roxana , Chen, Ruqin, Zhao, Yujie , Kang, Hye Seon , Li, Shenduo , Janus, Jeffrey R. , Pirgousis, Phillip , Patel, Samip , Okuyemi, Oluwafunmilola T., Singer, Elisha M., Tolaymat, Leila , Wysong, Ashley , Degesys, Catherine A. , Holtzman, Adam L. , Morecroft, Renee A , Phillipps, Jordan S, Dronca, Roxana S., Zhao, Yujie , Pirgousis, Phillip , Patel, Samip N , Wysong, Ashley , Barbosa, Naiara, Holtzman, Adam , Bhatt, Alok A , Gou, Lang, Doonan, Bently P. , Barbosa, Naiara S.

Mayo Clinic

Cancers | December 8, 2025 | Volume: 17 | Issue: 24 | Pages: 3921

10.3390/cancers17243921 | PMID 41463172 Get It

Localized cutaneous squamous cell carcinoma (cSCC) has a favorable prognosis, unlike advanced disease, especially with clinical perineural invasion (PNI), which poses substantial management challenges due to aggressivity and higher recurrence, metastasis, and mortality risks. PNI, a high-risk staging feature, has worse outcomes, particularly when clinically evident rather than incidental. Clinical PNI (cPNI) is evident by clinical symptoms (such as pain, paresthesia, or motor deficits) or radiologic findings, whereas incidental PNI (iPNI) is identified only histologically without associated symptoms or radiologic evidence. PNI remains a novel area with varying practice patterns across institutions. Improving risk stratification and tailoring multidisciplinary approaches are critical for optimizing outcomes. Our review outlines clinical practice patterns at our institution, providing insights into managing cSCC with PNI, focusing on diagnosis, imaging, staging, and emerging immunotherapies. A structured search was conducted using the terms “perineural invasion,” “cutaneous squamous cell carcinoma,” and “immunotherapy.” cPNI has a poor prognosis and requires nuanced clinical decision-making. Surgery and radiation remain central to management. Adjuvant therapy offers substantial survival benefit in cSCC with PNI, with improved disease-free and overall survival compared with surgery alone, supporting its use in appropriately selected high-risk patients. Traditional systemic therapies, including cisplatin and cetuximab, remain foundational but have shown only moderate response rates and limited durability in advanced or neurotropic cSCC. In contrast, immunotherapy—now preferred for advanced or unresectable cases—has transformed management, with programmed cell death protein-1 (PD-1) inhibitors showing promising results (up to 69% response rate) and disease stabilization. Neoadjuvant immunotherapy may enable tumor downstaging, improve radiation planning, and reduce surgical morbidity. Imaging for squamous cell carcinoma (SCC) with PNI aids staging and surveillance, but symptoms remain key for detecting recurrence. Our multidisciplinary approach emphasizes personalized care. Larger trials are needed to define the optimal role and sequencing of immunotherapy in this high-risk patient population.
Multiscale Segmentation-Guided Diffusion Model for CBCT-to-CT Synthesis
Guo, Yike, Luo, Yi , Hooshangnejad, Hamed , Zhang, Rui , Feng, Xue , Chen, Quan , Ngwa, Wilfred , Ding, Kai , Chen, Quan , Feng, Xue , Ding, Kai , Guo, Yike

Mayo Clinic

Life | December 8, 2025 | Volume: 15 | Issue: 12 | Pages: 1871

10.3390/life15121871 | PMID 41465810 Get It

To improve synthetic CT (sCT) generation from cone-beam CT (CBCT) in radiotherapy, we propose a multiscale segmentation-guided diffusion framework. The proposed model integrates anatomical priors across multiple spatial resolutions through a segmentation mask pyramid and introduces a scale-specific loss function to guide learning at each level. When evaluated on the SynthRAD2023 brain dataset, our model achieves a mean absolute error (MAE) of 61.82 HU, a peak signal-to-noise ratio (PSNR) of 32.05 dB, and a structural similarity index (SSIM) of 0.90, outperforming baseline models. These results suggest that multiscale anatomical guidance can improve the fidelity and anatomical consistency of sCT images, thus facilitating high-quality CBCT-to-CT translation in radiotherapy applications.
Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis
Kong, Xue, Xu‐Monette, Zijun Y. , Xu, Zhenming , Zhao, Xiaoxian , Nunns, Harry , Visco, Carlo , Tzankov, Alexandar , Dybkær, Karen , Yao, Shuna , Wu, Dehong , Wang, Chang , Pan, Zenggang , Parsons, Benjamin M. , Chiu, April , Tam, Wayne , Zhan, Fenghuang , Bernal‐Mizrachi, Leon , Zu, Youli , Zhang, Shanxiang , Chen, Weina , Au, Qingyan , Merchant, Akil , Bhagat, Govind , Young, Ken H. , Visco, Carlo , Dybkaer, Karen , Wang, Chang , Xu, Alexander M , Pan, Zenggang , Parsons, Benjamin M , Chiu, April , Zhan, Fenghuang , Møller, Michael Boe , Chen, Weina , Merchant, Akil , Bhagat, Govind , Li, Yong , Young, Ken H , Tzankov, Alexandar , Zu, Youli , Xu-Monette, Zijun Y , Hsi, Eric D. , Yan, Hui Min , Au, Kelly, Xu, Alexander M. , Montes‐Moreno, Santiago , Møller, Michael , Li, Yong

Mayo Clinic

Blood Advances | December 5, 2025 | Volume: 10 | Issue: 5 | Pages: 1756-1772

10.1182/bloodadvances.2025017643 | PMID 41346287 Get It

Abstract Pyroptosis is a form of programmed cell death characterized by the cleavage of the gasdermin (GSDM) family proteins that form pores in the plasma membrane, cell rupture, and the release of proinflammatory cytokines. In this study, we performed immunohistochemistry for cleaved gasdermin D (GSDMD), gasdermin E (GSDME) N-terminus, and gasdermin C (GSDMC) in 2 different cohorts of diffuse large B-cell lymphoma (DLBCL) and analyzed the impact of GSDM expression on prognosis and immunity. The results showed frequent cleaved GSDMD (N-terminal) expression. Only cytoplasmic GSDMD N-terminal expression correlated with significantly better patient survival in the 2 cohorts. In contrast, GSDME was mainly expressed in the vascular endothelium, and correlated with significantly adverse prognostic effect. Correlating with the multiplex fluorescent immunohistochemistry results, we found that cytoplasmic GSDMD N-terminal expression was associated with increased CD38+ (activated) M1 macrophages in both cohorts, cognate interactions between live DLBCL cells and activated M1 macrophages (and T cells), and lower PD-1/PD-L1 expression in the analyzed cases. In contrast, T-cell pyroptosis, lymphoma cell-resistance to cell death, and phagocytosis by M2 macrophages were observed in tissues with predominantly nuclear GSDMD N-terminal expression. Bulk gene expression profiling and deconvolution analysis revealed associations of cytoplasmic GSDMD N-terminal expression with downregulation of “Don’t eat me”–signaling genes, upregulation of many RNA genes, decreased frequency of “inflammatory” lymphoma microenvironment subtype, increased frequencies of prognostically favorable cell states and ecotypes, and decreased frequency of T-cell exhaustion state. In summary, this study showed distinct cellular and subcellular patterns of 3 GSDM proteins and their associated immune response phenotypes and prognostic effects, with implications for novel therapeutic strategies for B-cell lymphoma.